Effects of age and sex on the disposition of retigabine

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 1, 2003, Pages 61-70

  Hermann, Robert ^a,b   Ferron, Geraldine M ^a,b   Erb, Katharina ^a,b   Knebel, Norbert ^a,b   Ruus, Peter ^a,b   Paul, Jeffrey ^a,b   Richards, Lyette ^a,b   Cnota, Hans Peter ^a,b   Troy, Steven ^a,b  

^a A Viatris Company   (Germany)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; AWD 21360; DRUG METABOLITE; POTASSIUM CHANNEL; RETIGABINE; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ACETYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENDER; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTICONVULSANTS; AREA UNDER CURVE; CARBAMATES; CREATININE; FEMALE; HALF-LIFE; HUMANS; MALE; PHENYLENEDIAMINES; REFERENCE VALUES; SEX CHARACTERISTICS;

EID: 0037261396     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2003.12     Document Type: Article

References (35)

1. Sandercock PAG, Mumford CJ. Neurological disease. In: Axford J, editor. Medicine. Oxford (UK): Blackwell Science; 1996. p. 6-41.
2. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;334:1583-90.
3. Brodie MJ, French J. Management of epilepsy in adolescents and adults. Lancet 2000;356:323-9.
4. Walker MC, Sander JW. New anti-epileptic drugs. Expert Opin Investig Drugs 1999;10:1497-510.
5. Sabers A, Gram L. Newer anticonvulsants. Comparative review of drug interactions and adverse effects. Drugs 2000;60:23-33.
6. Rostock A, Tober C, Rundfeldt C, Bartsch R, Engel J, Polymeropoulos EE, et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res 1996;23:211-23.
7. Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur J Pharmacol 1996;303:163-9.
8. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by 4-aminopyridine in rat entorhinal cortex hippocampal slices. Naunyn Schmiedebergs Arch Pharmacol 1999;359:33-9.
9. Armand V, Rundfeldt C, Heinemann U. Effects of retigabine (D-23129) on different patterns of epileptiform activity induced by low magnesium in rat entorhinal cortex hippocampal slices. Epilepsia 2000;41:28-33.
10. Wang HS, Pan Z, Shi W, Brown BS, Wymore RS, Cohen US, et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science 1998;282:1890-3.
11. Rundfeldt C, Netzer R. The novel anticonvulsant retigabine activates M-currents in Chinese hamster ovary-cells transfected with human KCNQ2/3 subunits. Neurosci Lett 2000;281:73-6.
12. Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA, et al. Modulation KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol Pharmacol 2000;58:253-62.
13. Wickenden AD, Yu WF, Zou A, Jegla T, Wagoner PK, et al. Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol Pharmacol 2000;58:591-600.
14. Wickenden AD, Zou AR, Wagoner PK, Jegla T. Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells. Br J Pharmacol 2001;132:381-4.
15. Hirsch E, De Saint-Martin A, Marescaux C. Benign neonatal familial convulsions: a model of idiopathic epilepsy. Rev Neurol (Paris) 1999;155:463-7.
16. Rundfeldt C, Netzer R. Investigation into the mechanism of action of the new anticonvulsant retigabine. Interaction with GABAergic and glutamatergic neurotransmission and with voltage gated ion channels. Arzneimittelforschung 2000;50:1063-70.
17. Kapetanovic IM, Rundfeldt C. A new anticonvulsant compound. CNS Drug Rev 1996;2:308-21.
18. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J Clin Pharmacol 2002;42:175-82.
19. Benowitz NL, Perez-Stable EJ, Fong I, Modin G, Herrera B, Jacob P III. Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther 1999;291:1196-203.
20. Hempel R, Schupke H, McNeilly PJ, Heinecke K, Kronbach C, Grunwald C, et al. Metabolism of retigabine (D-23129), a novel anticonvulsant. Drug Metab Dispos 1999;27:613-22.
21. McNeilly PJ, Torchin CD, Anderson LW, Kapetanovic IM, Kupferberg HJ, Strong JM. In vitro glucuronidation of D-23129, a new anticonvulsant, by human liver microsomes and liver slices. Xenobiotica 1997;27:431-41.
22. Hiller A, Nguyen N, Strassburg CP, Li Q, Jainta H, Pechstein B, et al. Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos 1999;27:605-12.
23. Radominska-Pandya A, Little JM, Pandya JT, Tephly TR, King CD, Barone GW, et al. UDP-glucuronyltransferases in human intestinal mucosa. Biochem Biophys Acta 1998;1394:199-208.
24. Strassburg CP, Mann MP, Tukey RH. Expression of UDP-glucuronyltransferase 1A locus in human colon. J Biol Chem 1998;273:8719-26.
25. Hermann R, Schneider E, Menth M, Knebel N, Ferron GM, Borlak J, et al. Retigabine. In: Bialer M, Johannessen S, Kupferberg H, Levy R, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51:36-8.
26. Rowland M, Tozer TN. Age and weight. In: Rowland M, Tozer TN, editors. Clinical pharmacokinetics. Concepts and applications. 3rd ed. Baltimore (MD): Williams & Wilkins; 1995. p. 230-47.
27. Dawling S, Crome P. Clinical pharmacokinetics in the elderly. Clin Pharmacokinet 1989;17:236-63.
28. Kinirons MT, Crome P. Clinical pharmacokinetic considerations in the elderly. An update. Clin Pharmacokinet 1997;33:302-12.
29. Haemmerlein A, Derendorf H, Lowenthal DT. Pharmacokinetic and pharmacodynamic changes in the elderly. Clin Pharmacokinet 1998;35:49-64.
30. Mayersohn M. Pharmacokinetics in the elderly. Environ Health Perspect 1994;102:119-24.
31. Thürmann P, Hompesch BC. Influence of gender on the pharmacokinetics and pharmacodynamics of drugs. Int J Clin Pharmacol Ther 1998;36:586-90.
32. Poolsup N, Li Wan Po A, Knight TL. Pharmacogenetics and psychopharmatherapy. J Clin Pharm Ther 2000;25:197-220.
33. Knebel NG, Grieb S, Leisenheimer S, Locher M. Determination of retigabine and its acetyl metabolite in biological matrices by on-line solid-phase extraction (column switching) liquid chromatography with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl 2000;748:97-111.
34. Narayanan S, Appleton HD. Creatinine: a review. Clin Chem 1980;26:1119-26.
35. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Baltimore (MD): Williams & Wilkins; 1995.